Drug-Patent Cliffs
Invest in

Drug-Patent Cliffs

33.6%
3.5%
1.6%

Expiring Patents, Aspiring Generics

Big Pharma is headed for a big change. And generics are getting ready to grab their share. Branded drugs with sales of $86 billion would lose patent protection during 2013 to 2017.[1] Some of the most lucrative targets for generics in 2013 include Eli Lilly’s Cymbalta, Biogen Idec’s Avonex and Merck KGaA's Rebif. These drugs generated global sales worth $10 billion in 2012.[2] Generic drugs, once available, are typically 30% to 80% cheaper than the brand names, and can capture 80% of the market within the first year.[3] Which means the next few years hold an unprecedented growth opportunity for the generic drug industry. And that has investors feeling feverish. See more
33.6%
3.5%
1.6%
Invest in Thematic Portfolios
Create your own customizable basket of up to 30 stocks or ETFs for just $9.95.
Motif Index 1 YR Return
Drug-Patent Cliffs Benchmark
With this Motif, you can buy the following basket of stocks for just $9.95:
Weight Segment & Stocks Symbol 1 MO / 1 YR Return
66.0% Generic Drugs 27.2%
20.0% Perrigo Co. PRGO 27.4%
14.8% Mylan NV MYL --
7.4% Dr. Reddys Laboratories Ltd. ADS RDY 32.4%
6.0% Taro Pharmaceutical Industries Ltd. TARO 22.7%
4.4% Akorn Inc. AKRX 46.0%
4.1% Mallinckrodt plc MNK 55.9%
2.9% Impax Laboratories Inc. IPXL 54.8%
2.0% Sagent Pharmaceuticals Inc. SGNT 2.4%
1.2% Amphastar Pharmaceuticals Inc (DE) AMPH 81.7%
1.2% Cambrex Corp. CBM 117.3%
1.1% Igi Laboratories Inc IG 20.0%
1.0% Lannett Co. Inc. LCI 24.7%
28.9% Big Pharma 16.5%
24.6% Teva Pharmaceutical Industries TEVA 15.1%
4.4% Abbott Laboratories ABT 24.0%
5.1% Biosimilars 27.4%
1.5% Momenta Pharmaceuticals Inc. MNTA 93.9%
1.4% Pfenex Inc PFNX --
1.3% Coherus BioSciences Inc CHRS --
1.0% EPIRUS Biopharmaceuticals Inc EPRS --